BPG is committed to discovery and dissemination of knowledge
Randomized Clinical Trial
Copyright: ©Author(s) 2026.
World J Gastroenterol. Jul 7, 2026; 32(25): 119434
Published online Jul 7, 2026. doi: 10.3748/wjg.119434
Table 4 Summary of treatment-emergent adverse events (per safety set), n (%)

Fexuprazan 40 mg (n = 52)
Rabeprazole 20 mg (n = 54)
P value1
TEAE3 (5.77)2 (3.70)0.676
    95%CI1.20-15.950.45-12.75
Serious TEAE0 (0.00)0 (0.00)
Drug-related TEAE0 (0.00)2 (3.70)0.495
    95%CI-0.45-12.75
Serious drug-related TEAE0 (0.00)0 (0.00)


Write to the Help Desk